This may explain why anti-angiogenic monotherapies – such as a humanized monoclonal antibody that binds to and sequesters VEGF-A rendering it signaling-incapable (Avastin/Bevacizumab) has produced only limited improvements for breast cancer patients (49). Here, VEGFA is linked to breast carcinoma.